Stockscreener 앱 받기
48.47
0.12%
0.06
시간 외 거래:
48.61
0.14
+0.29%
전일 마감가:
$48.41
열려 있는:
$47.33
하루 거래량:
700.11K
Relative Volume:
0.57
시가총액:
$1.99B
수익:
$147.17M
순이익/손실:
$-408.35M
주가수익비율:
-4.3359
EPS:
-11.1787
순현금흐름:
$-299.92M
1주 성능:
+9.31%
1개월 성능:
-52.26%
6개월 성능:
+16.37%
1년 성능:
+73.05%
1일 변동 폭
$46.60
$49.75
1주일 범위
$41.53
$51.49
52주 변동 폭
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
명칭
Grail Inc
전화
(833) 694-2553
주소
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
48.47 | 1.99B | 147.17M | -408.35M | -299.92M | -11.18 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 업그레이드 | TD Cowen | Hold → Buy |
| 2026-02-19 | 개시 | TD Cowen | Hold |
| 2026-02-17 | 개시 | Robert W. Baird | Outperform |
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-11-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-04-21 | 개시 | Canaccord Genuity | Buy |
| 2024-11-27 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-10-17 | 개시 | Guggenheim | Neutral |
모두보기
Grail Inc 주식(GRAL)의 최신 뉴스
GRAIL, Inc. Opens with 5.11% Gain, Outperforming S&P 500's 1.01% Rise - Markets Mojo
The Escalator: Biogen, Flagship Pioneering, Grail and more - Medical Marketing and Media
Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction - MSN
Grail stock jumps after TD Cowen upgrade on cancer test outlook By Investing.com - Investing.com Australia
Grail stock jumps after TD Cowen upgrade on cancer test outlook - Investing.com
Grail stock upgraded at TD Cowen after selloff (GRAL:NASDAQ) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Trading Up 6.9% Following Analyst Upgrade - MarketBeat
Here’s what analysts are saying about Grail Inc. (GRAL) - MSN
LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED - PR Newswire
GRAIL (NASDAQ:GRAL) Raised to Buy at TD Cowen - MarketBeat
TD Cowen upgrades Grail stock rating to buy on cancer detection market potential - Investing.com
GRAIL, Inc. (NASDAQ:GRAL) Sees Significant Increase in Short Interest - MarketBeat
Does GRAIL (GRAL) Elevating Josh Ofman to CEO Reframe Its Management Quality Narrative? - simplywall.st
GRAIL names Josh Ofman as CEO, Bob Ragusa to retire June 1 - Investing.com Nigeria
Grail CEO Bob Ragusa to retire - MedTech Dive
Farallon Capital Management LLC Buys 847,000 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL, Inc. (NASDAQ:GRAL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Is GRAIL’s Research Platform Drawing Biotechnology Attention? - Kalkine Media
GRAIL announces leadership transition - MSN
Assessing GRAIL (GRAL) Valuation After Recent Share Price Pullback And Ongoing Growth Challenges - Yahoo Finance
Canaccord Genuity Reaffirms Their Buy Rating on GRAIL Inc (GRAL) - The Globe and Mail
GRAIL Inc (GRAL) Shares Down 4.59% on Mar 13 - GuruFocus
Assessing GRAIL (GRAL) Valuation After Recent Share Price Volatility and Narrative Fair Value Gap - simplywall.st
Grail Inc. Announces CEO Transition - Contract Pharma
Grail CEO to retire after failed cancer detection trialSan Francisco Business Times - The Business Journals
GRAIL, Inc. Hits Day High with 12.18% Surge Amid Market Challenges - Markets Mojo
(GRAL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Freidin, Grail CFO, sells $154k in GRAL stock - Investing.com Nigeria
Grail CEO Bob Ragusa retiring, Josh Ofman appointed successor - TipRanks
GRAIL, Inc. 2025 Annual Report: Multi-Cancer Early Detection with Galleri, Company Strategy, and Key Business Risks - Minichart
GRAIL, Inc. Announces Chief Executive Officer Changes, Effective June 1, 2026 - marketscreener.com
Cancer detection company GRAIL elevates Josh Ofman to lead multi-cancer efforts - Stock Titan
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - marketscreener.com
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity - AOL.com
Grail Inc’s Earnings Call Balances Momentum and Risk - TipRanks
A Persistent Patient’s Story - RealClearHealth
Archaeopteryx | The Holy Grail of Fossils at the Field Museum - Britannica
GRAIL (NASDAQ:GRAL) CEO Sells $51,949.80 in Stock - MarketBeat
Aaron Freidin Sells 2,492 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
Joshua Ofman Sells 2,937 Shares of GRAIL (NASDAQ:GRAL) Stock - MarketBeat
GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 655 Shares - MarketBeat
Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 7,461 Shares of Stock - MarketBeat
Freidin, Grail CFO, sells $154k in GRAL stock By Investing.com - Investing.com Australia
Ofman Joshua J. (GRAIL) sells $177k in shares - Investing.com South Africa
Grail CEO Ragusa sells $409k in shares - Investing.com India
CFO at GRAIL (GRAL) executes 3,147-share automatic sell-to-cover - Stock Titan
GRAIL (GRAL) president sells 3,627 shares in automatic tax sell-to-cover - Stock Titan
GRAIL2026 Funding Rounds & List of Investors - Tracxn
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - samsung.com
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - The Cancer Letter
GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg to differ - The Cancer Letter
Grail Inc (GRAL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):